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Background: The Bethesda system for reporting thyroid cytopathology (TBSRTC) was
introduced to standardize the communication of fine-needle aspiration cytology (FNAC)
interpretation between clinicians and pathologists. This study was undertaken to evaluate
the diagnostic utility of TBSRTC for reporting thyroid FNACs and rate of malignancy in each
diagnostic category of TBSRTC.
Methods: A total of 603 thyroid FNAC results were retrieved retrospectively between July
2012 and January 2015 and reclassified according to TBSRTC. Of these, 392 cases had a
histopathological follow-up. The FNACs results were compared to the histopathological
diagnoses and the malignancy rates of each diagnostic categories of TBSRTC were
calculated.
Results: Of the 603 FNACs, nondiagnostic were 16 (2.7%), benign were 393 (65.2%), atypia of
undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) were
60 (10%), follicular neoplasm/suspicious for a follicular neoplasm (FN/SFN) were 64 (10.6%),
suspicious for malignancy (SM) were 32 (5.3%), and malignant were 38 (6.3%). In 392 cases,
there was follow-up histopathology. The malignancy rate for nondiagnostic, benign, AUS/
FLUS, FN/SFN, SM, and malignant categories were 0%, 0.8%, 24.4%, 28.9%, 70.8%, and 100%,
respectively.
Conclusion: Our study validated the efficacy of TBSRTC. In conclusion, the malignancy rate
of AUS/FLUS in this study was higher than the risk mentioned in TBSRTC and other pub-
lished studies. Hence, AUS/FLUS category patients in our setup warrant further workup
including ultrasound and/or thyroid scan in addition to immediate repeat FNAC.ology, Dhanalakshmi Srinivasan Medical College and Hospital, Siruvachur, Perambalur, 621
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Scientific background on the subject
There is some lack of uniformity with regards to the
reporting terminology for thyroid cytology used by
pathologists worldwide, resulting in the miscommu-
nication of results among healthcare providers. We
evaluated the diagnostic utility of Bethesda system for
reporting thyroid cytopathology and the rate of
malignancy in each diagnostic category of Bethesda
system.
What this study adds to the field
Using Bethesda reporting system is likely to result in the
better communication of pathological data to clinicians
and allows easy and reliable sharing of information
among healthcare providers. Usage of atypia of unde-
termined significance/follicular lesion of undetermined
significance category seems to be disproportionately
high and this needs to be further evaluated using inter-
observer correlation studies.Fig. 1 e Fine-needle aspiration cytology of adenomatoid
nodule in nodular colloid goiter is showing clusters and
singly scattered follicular epithelial cells in the background
of colloid (H and E, 100).Fine-needle aspiration cytology (FNAC) is considered a
useful simple preoperative technique for triaging patients
with thyroid nodules [1]. Most of the thyroid nodules are
benign and approximately 5e10% are malignant requiring
operative and medical management. Hence, it is important to
differentiate benign nodules frommalignant nodules to avoid
unnecessary surgery [2,3]. Reporting of FNAC of the thyroid
using a standard terminology is not yet widely implemented.
The diagnostic terminology varies between pathologists and
even institutions creating confusion in the sharing of data
between pathologists and clinicians [4]. In an attempt to
address this problem, multiple organizations have proposed
diagnostic guidelines for reporting thyroid FNAC results
including the Papanicolaou Society of Cytopathology Task
Force and the American Thyroid Association, however, none
have been universally accepted [5,6]. To achieve the stan-
dardization of morphological criteria and diagnostic termi-
nology for the reporting of thyroid FNAC, in 2007, the
National Cancer Institute (NCI) organized the NCI thyroid
fine-needle aspiration state of the science conference which
proposed a 6 tier system named The Bethesda system for
reporting thyroid cytopathology (TBSRTC) [7,8]. The six
diagnostic categories namely nondiagnostic or unsatisfac-
tory, benign, atypia of undetermined significance/follicular
lesion of undetermined significance (AUS/FLUS), follicular
neoplasm/suspicious for a follicular neoplasm (FN/SFN),
suspicious for malignancy (SM), and malignant [7,8]. This
system also describes the malignancy risk in each category
and their recommended clinical management. The risks of
malignancy in nondiagnostic or unsatisfactory, benign, AUS/
FLUS, FN/SFN, SM, and malignant were 1e4%, 0e3%, 5e15%,
15e30%, 60e75%, and 97e99%, respectively [8]. This study
was undertaken to evaluate the diagnostic utility of TBSRTCfor reporting thyroid FNACs and the rate of malignancy in
each diagnostic category of TBSRTC.Materials and methods
After obtaining approval from the Institutional Ethical Com-
mittee, all the FNACs of thyroid lesions between July 2012 and
January 2015 were retrieved retrospectively. The slides were
stained by hematoxylin and eosin (H and E) and May-
Grunwald Giemsa. A total of 603 cases of FNACs were
included in this study. The FNACs were reclassified according
to the 6 tier diagnostic categories of TBSRTC [8].Satisfactory for evaluation
The specimen was considered satisfactory for evaluation if it
contains at least six groups of benign follicular cells, each
group composed of at least 10 cells.Nondiagnostic or unsatisfactory
The specimenwas considered nondiagnostic when it contains
predominantly blood or overly thick smears or absence of
colloid or an insufficient number or fixation quality of follic-
ular cells. Aspirates diagnosed as cyst fluid containing mac-
rophages only also categorized as nondiagnostic.Benign
The cases were categorized as benign if they showed the
cytomorphological features of nodular colloid goiter, chronic
lymphocytic thyroiditis, hyperplastic or adenomatoid nodule
[Fig. 1], thyrotoxicosis, and de Quervain's thyroiditis or gran-
ulomatous thyroiditis.
Fig. 3 e Histopathological section of papillary carcinoma of
thyroid showing fibrovascular core and tumor cells with
ground glass nuclei (H and E, 400).
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undetermined significance
This category was diagnosed when cases that cannot be
classified into any of the diagnostic categories of Bethesda
system and showing nuclear or architectural atypia [Fig. 2].
Follicular neoplasm/suspicious for a follicular neoplasm
Smears consisting of follicular cells of moderate to high
cellularity, scant to the absent colloid, and predominantly
repetitive microfollicular or trabecular configuration were
interpreted as FN/SFN. The cases showing morphological
features of hurthle cell neoplasm were also included in this
category.
Suspicious for malignancy
The cases showing cytomorphological features suggestive of
papillary carcinoma, medullary carcinoma, lymphoma, or
metastatic carcinoma were categorized as SM.
Malignant category
The aspirate revealing cytomorphological features of the
conclusive evidence of malignancy were placed in this cate-
gory. The malignancies included in this category were a
papillary carcinoma, medullary carcinoma, anaplastic carci-
noma, lymphoma, and metastatic carcinoma.
Follow-up cytology and histopathology
Of the 603 FNAC cases, 392 cases subsequently underwent
surgical intervention. The tissue specimens processed
routinely and 4 mmsectionswere cut and stainedwithH and E.
The results of final histopathological diagnoses [Fig. 3] were
compared to FNAC diagnoses and to find out malignancy rate
of each categories of TBSRTC. Papillary microcarcinoma
(<1 cm) on resection were not considered malignant exceptFig. 2 e Fine-needle aspiration cytology of atypia of
undetermined significance/follicular lesion of undetermined
significance showing follicular epithelial cells with nuclear
atypia (MGG, 100).when the prior cytologic interpretation was SM or malignant,
because the subcentimeter foci would not be targeted by the
needle. In calculating, the malignancy follow-up rate for the
benign category, the total number of original FNAC diagnoses
was used as the denominator, as similarly performed in other
studies [9e12].
Frequency, percentage and malignancy rate were calcu-
lated using IBM SPSS 20. The results were compared to the
TBSRTC and published studies.Results
In total, 603 FNAC cases between July 2012 and January 2015
were reviewed and analyzed by Bethesda system. Of these,
nondiagnostic were 16 (2.7%), benign were 393 (65.2%), AUS/
FLUSwere 60 (10%), FN/SFNwere 64 (10.6%), SMwere 32 (5.3%),
andmalignant were 38 (6.3%) are shown in Table 1. Among theTable 1 e Distribution of FNAC diagnoses according to
Bethesda system (n ¼ 603).
Diagnostic category Number of cases (%)
Nondiagnostic 16 (2.7)
Benign 393 (65.2)
Nodular colloid goiter 185 (30.7)
Hashimoto's thyroiditis 174 (28.9)
Adenomatoid nodule/nodular hyperplasia 34 (5.6)
AUS/FLUS 60 (10)
FN/SFN 64 (10.6)
FN 64 (10.6)
SM 32 (5.3)
Suspicious for papillary carcinoma 32 (5.3)
Malignant 38 (6.3)
Papillary carcinoma 34 (5.6)
Follicular variant of papillary carcinoma 3 (0.5)
Medullary carcinoma 1 (0.2)
Abbreviations: AUS/FLUS: Atypia of undetermined significance/
follicular lesions of undetermined significance; FN/SFN: Follicular
neoplasm/suspicious for follicular neoplasm; SM: Suspicious for
malignancy; FNAC: Fine-needle aspiration cytology.
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sponding final histopathological diagnoses were available.
The distribution of 392 FNAC cases is shown in Table 2. The
correlation of 392 cases of FNAC diagnoses with correspond-
ing histopathological diagnoses was done. The malignancy
rates of 6 tier Bethesda categories are shown in Table 3.
Of the total FNAC (603) cases, 16 were nondiagnostic. Of
these, 10 had subsequent surgical resection specimens. None
of them showed malignancy on HPE; the malignancy rate for
the nondiagnostic category was 0%.
Of the cases, 393 were classified as a benign category.
Among these, 256 had follow-up histopathology and three
cases were turned out to be follicular carcinoma. The overall
malignancy rate for the benign category was 0.8%.
Of the 60 cases of AUS/FLUS, 41 had follow-up histopa-
thology. Of these, 10 cases were diagnosed as follicular car-
cinoma; thus malignancy rate for AUS/FLUS category was
24.4%.
We classified 64 cases as FN/SFN among 603 FNACs. Of
these, 45 had follow-up histopathology. Of these 45 cases, 13Table 2eDistribution of FNAC diagnoseswho undergone
surgical intervention (n ¼ 392).
Diagnostic category Number of cases (%)
Nondiagnostic 10 (2.6)
Benign 256 (65.3)
Nodular colloid goiter 118 (30.1)
Hashimoto's thyroiditis 117 (29.8)
Adenomatoid nodule/nodular
hyperplasia
21 (5.4)
AUS/FLUS 41 (10.5)
FN/SFN 45 (11.5)
FN 45 (11.5)
SM 24 (6.1)
Suspicious for papillary carcinoma 24 (6.1)
Malignant 16 (4.1)
Papillary carcinoma 14 (3.5)
Follicular variant of papillary carcinoma 1 (0.3)
Medullary carcinoma 1 (0.3)
Abbreviations: AUS/FLUS: Atypia of undetermined significance/
follicular lesions of undetermined significance; FN/SFN: Follicular
neoplasm/suspicious for follicular neoplasm; SM: Suspicious for
malignancy; FNAC: Fine needle aspiration cytology.
Table 3 e Correlation of FNAC and histopathological diagnose
Bethesda categories (n ¼ 392).
FNAC Histopat
Diagnostic
category
Number of
cases
Benign Follicular
adenoma
Hurthle cell
adenoma
Nondiagnostic 10 9 1 e
Benign 256 237 16 e
AUS/FLUS 41 7 24 e
FN/SFN 45 1 30 1
SM 24 7 e e
Malignant 16 e e e
Total 392 261 71 1
Abbreviations: FNAC: Fine-needle aspiration cytology; AUS/FLUS: Atypia
nificance; FN/SFN: Follicular neoplasm/suspicious for follicular neoplasmwere turned out to be follicular carcinoma; thus malignancy
rate for FN/SFN category was 28.9%.
Twenty-four out of 32 cases of SM were available for HPE.
Of these, 16 cases were found to be papillary carcinoma, and 1
case was diagnosed as follicular carcinoma; thus malignancy
rate for SM category was 70.8%.
We categorized 38 cases as malignant among 603 cases. Of
these, 16 had follow-up histopathology. All 16 cases were
found to be malignant with 14 cases of papillary carcinoma, 1
case of follicular variant of papillary carcinoma, and 1 case of
medullary carcinoma; thus the malignancy rate for malignant
category was 100%.Discussion
Thyroid enlargement is a common occurrence in the most
regions of the world. In India, the sub-Himalayan region has
the world's biggest goiter belt [13]. Thyroid enlargement
regardless of being diffuse or nodular should be investigated
mainly to rule out the possibility of a neoplasm or thyroiditis.
FNAC is usually the first line of investigation and other in-
vestigations such as ultrasound, thyroid profile, thyroid scan,
and serology are done subsequently with an aim to select the
patients who require surgical management and those require
medical management [14,15].
Reviewing of the FNAC slides in our study using 6 tier
diagnostic categories of Bethesda system, it seemed more
simplified, systematic, with great clarity; thus, it would be
more useful in guiding clinicians toward the management of
thyroid nodules [16]. We recognized that distribution of the
FNAC diagnoses of thyroid lesions using Bethesda system in
our institution showed slightly different statistical values
when compared with published studies [9e11,17e23], that are
shown in Table 4. The benign, SM, andmalignant categories of
our study were comparable to frequencies found by the most
of the published studies. However, the percentages of AUS/
FLUS, and FN/SFN categories were significantly higher than
other studies with a low percentage of a nondiagnostic cate-
gory [Table 4]. The heterogeneity and subjectivity could be the
reason for the higher percentage of AUS/FLUS category. Our
institute is a tertiary care center andwe have a high number of
referral patients who had been given an inconclusives and malignancy rate on surgically resected specimen for
hological diagnoses Malignancy
rate (%)Follicular
carcinoma
PCT Follicular
variant of PCT
Medullary
carcinoma
e e e e 0
3 e e e 0.8
10 e e e 24.4
13 e e e 28.9
1 16 e e 70.8
e 14 1 1 100
27 30 1 1
of undetermined significance/follicular lesions of undetermined sig-
; SM: Suspicious for malignancy; PCT: Papillary carcinoma of thyroid.
Table 4 e Comparison of the distribution of Bethesda diagnostic categories of the present study with published studies.
Study Year Number of cases Nondiagnostic (%) Benign (%) AUS/FLUS (%) FN/SFN (%) SM (%) Malignant (%)
Jo et al. [9] 2009 3080 18.6 59 3.4 9.7 2.3 7
Mondal et al. [10] 2012 1020 1.2 87.5 1 4.2 1.4 4.7
Mufti and Molah [11] 2010 250 11.6 77.6 0.8 4 2.4 3.6
Park et al. [17] 2011 1730 13.3 40.6 9.1 0.4 19.3 17.3
Williams et al. [18] 2010 1481 28.9 45.7 18.8 4.4 1.3 0.9
Theoharis et al. [19] 2008 3207 11.1 73.8 3 5.5 1.4 5.2
Al-shraim et al. [20] 2007 323 6.2 57.3 13.6 16.1 1.5 5.3
Nayar and Ivanovic [4] 2006 5194 5 64 18 6 2 5
Yang et al. [21] 2005 4703 10.4 64.6 3.2 11.6 2.6 7.6
Yassa et al. [22] 2004 3589 7 66 4 9 9 5
Present study 2014 603 2.7 65.3 10 10.6 5.3 6.3
Abbreviations: AUS/FLUS: Atypia of undetermined significance/follicular lesions of undetermined significance; FN/SFN: Follicular neoplasm/
suspicious for follicular neoplasm; SM: Suspicious for malignancy.
b i om e d i c a l j o u r n a l 3 8 ( 2 0 1 5 ) 5 1 7e5 2 2 521diagnosis in other hospitals. This could have been resulting in
a high number of FN/SFN cases in our study. The reason for
the low frequency of nondiagnostic category can be attributed
to the fact that, in our institute, ultrasound-guided FNAC was
performed for small nodules and it was done by well trained
and experienced pathologists.
We found malignancy rates of thyroid lesions in our study
were comparable with those mentioned in the Bethesda sys-
tem and also with published studies in most categories. The
malignancy rate of the nondiagnostic category of our study
was 0% similar toMondal et al. study [10] and it was the higher
inmost of the previous studies [17,18,21]. Themalignancy rate
of the benign category was 0.8% similar to Bethesda system, Jo
et al., Yang et al., and Yassa et al. studies [8,9,21,22]. The
malignancy rate of AUS/FLUS category (24.4%) was the higher
than those reported in the TBSRTC guidelines and few other
studies [4,8]. A study done by Layfield et al. [23] found that
there is a wide variation in the malignancy rate for AUS/FLUS
category diagnoses between the different institution and
among cytopathologists within the same institution,
depending on whether they had received cytopathology
fellowship training. Cibas et al. [8] stated that AUS/FLUS
category may never have good inter-observer reproducibility,
even after pathologists familiarize themselves with the
criteria. We had a histopathological specimens of 41 out of 60Table 5 e Comparison of themalignancy rates by FNAC categor
Study Year Number of cases Nondiagnostic (%)
Bethesda system [8] e e 1e4
Jo et al. [9] 2009 892 8.9
Mondal et al. [10] 2012 323 0
Mufti and Molah [11] 2010 84 20
Park et al. [17] 2011 1547 35.3
Williams et al. [18] 2010 388 18.2
Theoharis et al. [19] 2008 378 e
Al-shraim et al. [20] 2007 323 35
Nayar and Ivanovic [4] 2006 1413 9
Yang et al. [21] 2005 1052 10.7
Yassa et al. [22] 2004 1242 10
Present study 2014 392 0
Abbreviations: AUS/FLUS: Atypia of undetermined significance/follicular
suspicious for follicular neoplasm; SM: Suspicious for malignancy; FNACFNAC cases, thus the malignancy rate of AUS/FLUS in our
study may approximate the true malignancy risk for AUS/
FLUS. Some studies observed that the use of liquid-based
cytology can improve the diagnostic accuracy of AUS/FLUS.
The ultrasonographic findings such as hyper-echogenicity,
irregular nodule borders, calcifications, and vascular abnor-
malities are the features of malignancy [23]. Hence, AUS/FLUS
category patients in our setup warrant further workup
including ultrasound and/or thyroid scan in addition to im-
mediate repeat FNAC.
The malignancy rate of FN/SFN, SM, and malignant cate-
gories (28.9%, 70.8%, and 100% respectively) was similar to
most published studies [8e11,17e22], [Table 5]. The most of
the follicular carcinoma diagnosed in our studywere classified
as AUS/FLUS and FN/SFN. Hence, this study reinforces the
follicular neoplasm fall into AUS/FLUS or FN/SFN group since
cytology cannot detect capsular or vascular invasion to
differentiate follicular adenoma from carcinoma.
Even though this study provides useful information, there
are few limitations.
1. Clinico-radiological and biochemical correlation were not
available as it is a retrospective study.
2. The quality of staining was not good in some slides; hence,
we felt some difficulty in reporting of FNACs.y of present study, Bethesda system and published studies.
Benign (%) AUS/FLUS (%) FN/SFN (%) SM (%) Malignant (%)
0e3 5e15 15e30 60e75 97e99
1.1 17 25.4 70 98.1
4.5 20 30.6 75 97.8
3.1 50 20 80 100
5.6 69 50 98.7 98.9
16 24.7 32.6 94.1 100
9.8 48 34 87 100
10.3 15.9 32.7 60 94
2 6 14 53 97
0.7 19.2 32.2 64.8 98.4
0.3 24 28 60 97
0.8 24.4 28.9 70.8 100
lesions of undetermined significance; FN/SFN: Follicular neoplasm/
: Fine-needle aspiration cytology.
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Our study validated the efficacy of TBSRTC. In conclusion, the
malignancy rate of AUS/FLUS in this study was the higher
than the risk mentioned in TBSRTC and other published
studies. Hence, AUS/FLUS category patients in our setup
warrant further workup including ultrasound and/or thyroid
scan in addition to immediate repeat FNAC. Using this
reporting system can improve the communication between
the pathologists and clinicians and allows easy and reliable
sharing of data between institutions and laboratories.r e f e r e n c e s
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